Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

On-demand use of clomipramine effective, safe in men with premature ejaculation

28 Nov 2018

Use of clomipramine as an on-demand treatment of premature ejaculation is well tolerated and effective, with the results of a phase III study showing increased ejaculation time during vaginal penetration.

A total of 159 patients with premature ejaculation were randomized to receive clomipramine 15 mg (n=106) or placebo (n=53) orally for 12 weeks. Patients were instructed to take the drug around 2–6 hours prior to planned sexual intercourse. They underwent evaluations at baseline and every 4 weeks.

Treatment efficacy was evaluated using Intravaginal Ejaculation Latency Time (IELT) and Premature Ejaculation Diagnostic Tool (PEDT) scores.

After 12 weeks of treatment, the mean IELT significantly increased in the clomipramine 15 mg group than in the placebo group (intention-to-treat: 4.40±5.29 vs 2.68±2.03; p<0.05). Fold change of IELT in the per-protocol population was also significantly different between the two treatment groups, in favour of the active drug (mean: 4.66±5.64 vs 2.80±2.19; p<0.05).

Likewise, there was a significant between-group difference in PEDT scores, which were better with clomipramine vs placebo (p<0.001).

Adverse events were mild to moderate in severity. The most commonly reported were nausea (15.7 percent) and dizziness (4.9 percent).

A tricyclic antidepressant, clomipramine hydrochloride is indicated for obsessive-compulsive disorder, panic disorder and depressive disorder. The drug is said to be the most potent inhibitor of 5- hydroxytryptamine (serotonin) reuptake among antidepressants. Side effects include dry mouth, nausea, constipation, loss of appetite, fatigue and dizziness. [Int J Impot Res 2018;30:65-70]

Editor's Recommendations
Most Read Articles
5 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
3 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.